AIB1, identified as a coactivator for nuclear steroid hormone receptors, was initially found to be amplified and overexpressed in breast cancer 12, and it has subsequent been shown to be high expressed in other hormone-dependent tumors, such as prostate 34, 35, and ovarian cancer 36, and endometrial carcinoma 37. Here, NCOA3 is linked to ovarian cancer.